{
    "clinical_study": {
        "@rank": "139512", 
        "arm_group": {
            "arm_group_label": "Newrabell single arm", 
            "arm_group_type": "Experimental", 
            "description": "Newrabell\u00ae Tablet 10mg b.i.d PO during 8 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of Newrabell\u00ae Tab. in\n      patients with refractory reflux esophagitis to the prior standard PPIs regimen."
        }, 
        "brief_title": "The Study to Evaluate Efficacy and Safety of Newrabell\u00ae Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Reflux Esophagitis", 
        "condition_browse": {
            "mesh_term": [
                "Esophagitis", 
                "Esophagitis, Peptic", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or Female aged \u2265 20 years\n\n          2. Reflux esophagitis with erosion or ulceration confirmed by endoscopic exam.\n\n          3. Refractory reflux esophagitis to PPIs standard treatment as follows\n\n               1. Ongoing heartburn symptom with or without these GERD-related symptoms :\n                  Regurgitation, Non-cardiac chest pain, Epigastric pain, Belching, Bloating,\n                  Satiety, Sore throat, Cough, Laryngitis, Hoarseness, Nausea, Vomiting,\n                  Dysphagia, Odynophagia, Weight loss\n\n               2. Ongoing heartburn symptom with or without erosion \u2265 grade A according to LA\n                  Classification\n\n          4. Ongoing heartburn symptoms \u2265 2 days during 1week right before administering first\n             dose of IP\n\n          5. Decided to participate and signed on an informed consent form willingly\n\n        Exclusion Criteria:\n\n          1. Existence of upper gastrointestinal bleeding or active gastroduodenal ulcer at\n             screening\n\n          2. History of operation in esophagus, stomach or duodenum\n\n          3. The following medical history\n\n               1. Primary esophageal motility disease, Achalasia, Scleroderma, Esophageal/pyloric\n                  stricture, Primary esophageal spasm\n\n               2. Barrett's esophagus \u2265 3 cm\n\n               3. Zollinger-Ellison syndrome\n\n               4. Infectious or inflammatory bowel disease, Severe malabsorption\n\n          4. Severe chronic heart failure, cardiovascular disease, renal failure, COPD, asthma,\n             liver cirrhosis\n\n          5. History of cancer within 5 years, except completely recovered skin cancer\n\n          6. ALT or AST \u2265 Upper limit of normal range X 3\n\n          7. Need antibiotics due to severe infection\n\n          8. Severe medical disease that needs these prohibited medication\n\n               -  Anticoagulant(Heparin, Warfarin, etc.), High dose of aspirin(>325mg/d),\n                  Digitalis(Digoxin, etc.), Diuretics, Atazanavir, NSAIDs or Steroids\n\n          9. Use PPIs or H2RA medicine within 1 week before administering first dose of IP, or\n             need other PPIs or H2RA medicine during trial period\n\n         10. Allergy or hypersensitivity to IP or similar chemical structure(Benzimidazol\n             derivatives, etc.)\n\n         11. Pregnant or breast-feeding women\n\n         12. Conversation impairment because of alcohol, drug addiction or mental illness, etc.\n\n         13. Administration of other IP within 28 days\n\n         14. Inability to record heartburn diary card\n\n         15. In investigator's judgement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860482", 
            "org_study_id": "243GERD13003"
        }, 
        "intervention": {
            "arm_group_label": "Newrabell single arm", 
            "intervention_name": "Newrabell\u00ae Tablet 10mg", 
            "intervention_type": "Drug", 
            "other_name": "Rabeprazole sodium"
        }, 
        "intervention_browse": {
            "mesh_term": "Rabeprazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Refractory Reflux Esophagitis", 
            "GERD", 
            "Phase 4"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jsrew@jnu.ac.kr", 
                    "last_name": "Jongsun Rew, Ph.D", 
                    "phone": "+82-62-220-6202"
                }, 
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of", 
                        "state": "Donggu, Jebongro", 
                        "zip": "501-757"
                    }, 
                    "name": "Chonnam National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jongsun Rew, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "portalvein@naver.com", 
                    "last_name": "Sungbum Cho, Ph.D", 
                    "phone": "+82-61-379-7604"
                }, 
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of", 
                        "state": "Hwasun-eup,Hwasun-gun", 
                        "zip": "519-763"
                    }, 
                    "name": "Chonnam National University Hwasun Hospital"
                }, 
                "investigator": {
                    "last_name": "Sungbum Cho, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell\u00ae Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen", 
        "overall_contact": {
            "email": "jsrew@jnu.ac.kr", 
            "last_name": "Jongsun Rew, Ph.D", 
            "phone": "+82-62-220-6202"
        }, 
        "overall_contact_backup": {
            "email": "portalvein@naver.com", 
            "last_name": "Sungbum Cho, Ph.D", 
            "phone": "+82-61-379-7604"
        }, 
        "overall_official": [
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Jongsun Rew, Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Sungbum Cho, Ph.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to onset of first 1Day Heartburn free, Days", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860482"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to onset of first 2Days Heartburn free, Days", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "1Day Heartburn free days, %", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Time in Daytime of first Heartburn free, Days", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Time in Nighttime of first Heartburn free, Days", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Weekly Heartburn Improvement Rate, %", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Average Daytime and Nighttime Heartburn Score Change at W4", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Average Daytime and Nighttime Heartburn Score Change at W8", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}